Global RNAi Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global RNAi Drugs Market Insights, Forecast to 2034
It refers to the highly conservative, double stranded RNA induced, highly specific degradation of homologous mRNA in the evolutionary process
Global RNAi Drugs market is expected to reach to US$ 84010 million in 2024, with a positive growth of %, compared with US$ 69200 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, RNAi Drugs industry is evaluated to reach US$ 268930 million in 2029. The CAGR will be 21.4% during 2024 to 2029.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Covers
This report presents an overview of global RNAi Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Hospital
Clinic
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ RNAi Drugs plant distribution, commercial date of RNAi Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, RNAi Drugs introduction, etc. RNAi Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of RNAi Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global RNAi Drugs market is expected to reach to US$ 84010 million in 2024, with a positive growth of %, compared with US$ 69200 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, RNAi Drugs industry is evaluated to reach US$ 268930 million in 2029. The CAGR will be 21.4% during 2024 to 2029.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Covers
This report presents an overview of global RNAi Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Segment by Application
Hospital
Clinic
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ RNAi Drugs plant distribution, commercial date of RNAi Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, RNAi Drugs introduction, etc. RNAi Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of RNAi Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices